$LGND News

$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock

Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?

Ligand (LGND) Q2 2026 Earnings Call Transcript

LGND: XOMA Acquisition Closed

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...

Ligand Pharmaceuticals Q2 Earnings Call Highlights

HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue

Ligand Reports Second Quarter 2026 Financial Results

Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340

B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388